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Abstract
Background: Mycobacterium tuberculosis infection is known to cause inflammation and lung tissue damage in
high-risk populations. Nevertheless, direct associations between mycobacterial loads, systemic inflammation and
pulmonary lesions upon treatment initiation have not been fully characterized. In the present exploratory study, we
prospectively depict the immune profile, microbial clearance and evolution of radiographic lesions in a pulmonary
tuberculosis (PTB) patient cohort before and 60 days after anti-tuberculous treatment (ATT) initiation.
Methods: Circulating levels of cytokines (IL-2, IL-4, IL-6, IL-10, IFN-γ, TNF-α) and C-reactive protein (CRP), as well as
values of erythrocyte sedimentation rate (ESR) were measured in cryopreserved serum samples obtained from 73
PTB patients at pre-ATT and day 60 of treatment. Changes of the immune profile over time were compared with
mycobacterial loads in sputum and culture conversion at day 60 of ATT. Additional analyses tested associations
between improvement of chest radiographic lesions at day 60 and pre-treatment status of inflammation and
mycobacterial loads.
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Results: Within the inflammatory parameters evaluated, values of CRP, IL-2, IL-4, TNF-α and ESR significantly
decreased upon treatment initiation. On the converse, IL-10 levels substantially increased at day 60 of ATT, whereas
concentrations of IL-6 and IFN-γ remained unchanged. Multidimensional analyses revealed that ESR, IL-2, IL-4 and
CRP were the parameters with the highest power to discriminate individuals before and after treatment initiation.
We further demonstrated that higher bacterial loads in sputum at pre-ATT were associated with increased systemic
inflammation and higher risk for positive M. tuberculosis sputum cultures at day 60 of treatment. Furthermore, we
found that pre-ATT mycobacterial loads in sputum and systemic inflammation synergistically associated with the
status of radiographic lesions during treatment (Relative risk for chest X-ray improvement: 10.0, 95 % confidence
interval: 2.4–40.0, P = 0.002).
Conclusions: M. tuberculosis loads in sputum are directly associated to the status of systemic inflammation and
potentially impact the immune profile, culture conversion and evolution of lung lesions upon ATT initiation.
Keywords: Tuberculosis, Inflammation, C-reactive protein, Biomarker, Erythrocyte sedimentation rate, Acid-fast
bacilli, Anti-tuberculous treatment, Radiographic evaluation
Background
Upon M. tuberculosis infection, a host can develop a
wide range of disease manifestations ranging from
asymptomatic infection to severe progressive disease [1].
Importantly, only 10 % of individuals exposed to M. tu-
berculosis develop active disease, which highlights the
importance of understanding the key determinants of
susceptibility to infection. The determinants of the TB
clinical presentation are described to involve a complex
relationship between the mycobacterium and the host
immune responses [2, 3]. Successful host response
against M. tuberculosis requires the production of pro-
inflammatory cytokines including IFN-γ and TNF-α [4,
5]. Indeed, individuals genetically deficient in molecules
from the IFN pathway, as well as those under treatment
of chronic conditions with TNF-α blockers, are highly
susceptible to severe TB [6].
Existing blood-based tests, such as IFN gamma release
assays (IGRA) are inadequate for monitoring treatment
response [7]. Therefore, host biomarkers for monitoring
treatment response have been considered as important
priorities for TB research [8].
It has been recently described in distinct TB patient
cohorts from Brazil and India that TB disease severity is
associated elevated circulating levels of CRP and other
pro-inflammatory cytokines and lipid mediators [9, 10].
Although there have been indications from experimental
models that M. tuberculosis loads in the lungs are associ-
ated with the inflammatory profile and lung disease se-
verity [11, 12] this relationship has not been yet fully
investigated prospectively.
The present study addresses this question in a cohort
of PTB patients from a highly endemic area in Brazil.
The findings argue that there is a strong relationship be-
tween pre-treatment mycobacterial loads and systemic
inflammation, which may set the stage for persistence of
sputum culture positivity and radiographic improvement
after 2 months of antibiotic chemotherapy.
Methods
Study design
We performed a longitudinal cohort study involving 73
patients diagnosed with PTB and admitted to a referral
hospital for the treatment of TB in the state of Rio de
Janeiro, Brazil (Instituto Estadual Ary Pareiras), between
March 2007 and August 2009. We included subjects
from both sexes, infected or not by HIV, with positive
smear microscopy and culture for M. tuberculosis
complex subsequently confirmed by biochemical tests.
We excluded subjects aged under 18 and over
60 years; taking anti-TB drugs before admission, with
insulin-dependent diabetes mellitus, renal failure or
hemodialysis and peritoneal dialysis blood transfusion;
women in pregnancy or lactation period; and those
whose clinical samples were not subjected to bac-
teriological or laboratory tests. The outcome in our
study was to evaluate the frequency of negative cul-
ture at day 60 of treatment and its association with
bacteriological status, inflammatory profile and radio-
logical aspects observed at pre-ATT and day 60 of
ATT. Our study population was followed up very closely
to assure treatment adherence. During the study period,
all pulmonary TB patients included remained hospitalized
and received anti-TB drugs under directly observed man-
ner. For quality control purposes, we measured each in-
flammatory parameter in 10 age- and sex-matched healthy
individuals. This control group was composed by health
care professionals from our laboratory who were screened
negative from TB by means of negative Tuberculin Skin
Test (TST), negative IGRA assay, no symptoms and no le-
sions in chest X-ray.
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Radiographic evaluation
All patients underwent chest radiography in the pre-
ATT and day 60 in posterior-anterior (PA) and left pro-
file (LP). To improve the assessment of the quality of
images evaluated in this study, radiographs were digi-
tized at the Advanced Nuclei for High Performance
Computing, Federal University of Rio de Janeiro, Brazil.
Once scanned and saved, the images were viewed
analyzed by a two pulmonologists (E.M., A.K.), who were
blinded to the subjects clinical/demographic characteris-
tics, laboratory results and treatment outcome. A stan-
dardized case report form was used to document the
presence of following images, according to the chest
radiographs of the Committee of the Fleischner Society
[13]: volume loss, cavitation, consolidation, nodules, in-
filtrates, hilar lymph node enlargement, pleural effusion,
pleural thickening, lung sequel and bronchiectasis. The
location of consolidation or cavities was specified divid-
ing the lung into six zones (upper/middle/lower for each
lung). As a quality check, the senior radiologist (E.T.)
read each film, also blinded to original interpretations,
when discordance occurred between two pulmonolo-
gists. Thus, every third was analyzed for the presence of
the changes at pre-ATT and day 60. The ratings were
categorized as: (i) improvement or evolving to the sequel
and; (ii) no improvement when remained the disease ac-
tivity or lesions were suggestive of fibrosis and scarring.
Immunoassays
The serum levels of IL-2, IL-4, IL-6, IL-10, TNF-α and
IFN-γ were measured using a pre-determined multipara-
metric cytometry-based bead assay (Cytometric Bead
Array Human Th1/Th2 Cytokine Kit, BD Biosciences,
San Jose, CA) following the manufacturer’s protocol.
This assay provides a method of capturing a set of ana-
lytes with beads of known size and fluorescence, making
it possible to detect analytes using flow cytometry
(FACSCalibur; BD Biosciences) [14–16]. The concentra-
tions of samples were calculated by extrapolating the
mean fluorescence intensity (MFI) on the respective
standard curves. A single flow cytometry operator per-
formed the assays. Serum levels of CRP were determined
using an ELISA-based assay (Ebioscience, San Diego,
CA). Values of ESR were quantified at the clinical la-
boratory of the Federal University of Rio de Janeiro
using the Westergren method. The limits of detection of
the cytokines (in pg/mL) were: IL-2: 11.2, IL-4: 1.4, IL-6:
1.6, IL-10: 0.13, TNF-α: 1.2, IFN-γ: 0.8. The limit of de-
tection for CRP was 0.15 mg/L.
Data analysis
Median and interquartile ranges (IQR) were used as
measures of central tendency. Levels of inflammatory
markers were compared in the study population (and
subgroups) between pre-ATT and day 60 of treatment
using the Wilcoxon matched pairs test with Holm-
Bonferrori adjustment for multiple comparisons. Corre-
lations between the markers were assessed using the
Spearman rank test. Inferential network analysis was
performed using the statistically significant correlations
observed in the Spearman correlation matrices as previ-
ously described [17–20]. Briefly, each biomarker is se-
lected as a target, and the software (JMP 12.0, SAS,
Cary, NC, USA) performs a search within the other
mediators for those that are correlated, with the target
calculating a correlation matrix using Spearman rank
tests. As a result, the features related to the selected
target are linked. The links shown in the networks rep-
resent statistically significant Spearman rank correlations
(P < 0.05) after adjustments for multiple measurements
(Holm-Bonferrori’s method). Moreover, two models of
principal component analysis (PCA), as described previ-
ously [9, 21] were employed to test which combination
of inflammatory markers could better distinguish indi-
viduals before and after ATT initiation. Hierarchical
cluster analyses with bootstrap (100×) were performed
to describe the overall expression profile of inflamma-
tory markers in different settings. Comparisons of pro-
portions between study groups were tested using the
Fisher’s exact test. The same test was used to compare
frequency of patients displaying improvement in chest
X-ray lesion evaluation. Logistic regression analyses ad-
justed for age and gender were employed to verify the
associations between indicated variables and culture
positivity or radiographic improvement at day 60. All
analyses were pre-specified. Two-sided p values of <0.05
after adjustment for multiple comparisons were consid-
ered statistically significant. Statistical analyses were per-
formed using SPSS 20.0 (IBM statistics), Graphpad
Prism 6.0 (GraphPad Software, San Diego, CA) and JMP
12.0.
Results
Defining a biosignature of serum inflammatory markers
in TB patients undergoing ATT
A total of 73 PTB patients were prospectively studied
(median age: 41 years, interquartile range [IQR]: 29–50;
male 84 %; Table 1). The median hemoglobin value was
11.6 g/dL (IQR: 9.9–12.9 g/dL). Cavitary lesions were
identified in 42 patients (57.5 %). Multiple cavitations
(>1) were observed in 25 individuals (34.2 %). The vast
majority of the study population referred smoking
history (74.1 %) and alcoholism (72.6 %). Approxi-
mately 1/3 reported illicit drugs use (31 %). HIV sero-
positivity was 13 % (Table 1).
An exploratory analysis examined circulating levels of
inflammatory parameters, including cytokines such as
IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ, as well as CRP and
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ESR. We observed that CRP, IL-2, IL-4, TNF-α and ESR
values significantly decreased whereas concentrations of
IL-10 increased upon ATT initiation (Fig. 1a). Serum
levels of IL-6 and IFN-γ did not substantially change
between pre-ATT and day 60 of treatment (Fig. 1a). We
have recently shown that the statistical relationships
between inflammatory markers using network analysis
can help define the profile of the inflammatory milieu in
different disease models [17–20]. In the present study,
we detected that the overall profile of the correlations
between the serum markers changed between days 0
and 60 of anti-microbial therapy (Fig. 1b). Notably, there
were no significant negative correlations between the
parameters examined in this analysis. Moreover, at
pre-ATT, TNF-α was the marker that exhibited the
highest number of significant correlations with the
other parameters (Fig. 1b and Additional file 1). Intri-
guingly, amongst all the cytokines evaluated at this
time point, only IL-6 was significantly correlated with
CRP (r = 0.44, p = 0.003), and no robust association was
observed between the biomarkers and ESR (Fig. 1b). These
finding suggest that the cytokine inflammatory milieu was
not directly correlated with values of acute phase parame-
ters in PTB patients before treatment initiation. Upon
ATT, the most important node in the network of associa-
tions was IFN-γ (Fig. 1b). Interestingly, at day 60 of treat-
ment, IFN-γ levels became positively correlated with CRP
(r = 0.39, p = 0.009) and ESR (r = 0.38, p = 0.01), arguing
that individuals on ATT who remained with higher levels
of this cytokine exhibited increased systemic inflammation.
We next employed a PCA model inputting values of
the cytokines and acute phase parameters and observed
that the overall pattern of systemic inflammation could
distinguish PTB patients at the different study time
points (Fig. 1c). A complementary vector analysis re-
vealed that ESR, IL-4, IL-2 and CRP were the most
important factors determining the discrimination power
of the PCA model (Fig. 1c). To confirm this result, we
designed a second PCA model including all the parame-
ters except for ESR, IL-4, IL-2 and CRP. In this new
model, patients grouped according to the study time
point were no longer distinguishable (Fig. 1d).
Higher mycobacterial loads in sputum smears are
associated increased risk for culture positivity at day 60
of ATT
Previous studies have suggested that presence of M.
tuberculosis in sputum is associated with more severe
clinical forms of TB, which is reflected by elevated
levels of acute phase reactants [10]. To test if the
mycobacterial loads in sputum are associated with
systemic inflammation in our patient cohort, we per-
formed a hierarchical cluster analysis of the serum levels
of the inflammatory markers as well as values of ESR in
patients stratified by acid-fast bacilli (AFB) smear grade at
pre-ATT. We confirmed that patients with higher myco-
bacterial loads in sputum smears indeed exhibit a distinct
pro-inflammatory signature profile (Fig. 2a). Interestingly,
CRP values were the highest in individuals with AFB
2+ whereas ESR values were higher in those with
AFB 1+, leading us to speculate that the relationships
observed between mycobacterial loads in sputum and
circulating cytokine levels may not be strictly repre-
senting the degree of systemic inflammation and may
rather highlight qualitative differences in inflammation
and/or immune response. Additional analyses using
Spearman correlation ranks tested whether each indi-
vidual inflammatory parameter are correlated with the
AFB smear grade values. Of note, amongst all the pa-
rameters, only CRP (r = 0.28, p = 0.04), IL-6 (r = 0.33,
p = 0.035) and IL-10 (r = 0.39, p = 0.02) were modestly
associated with mycobacterial loads in sputum. Further-
more, we prospectively assessed changes in the inflamma-
tory biosignature profile from day 0 to day 60 of ATT in
patients presenting with positive or negative AFB staining
at the study enrollment. Hemoglobin concentrations
consistently increased after implementation of anti-
tuberculous therapy (median 12.8 g/dL, IQR: 11.4–14.2 on
day 60 of ATT vs. median 11.6 g/dL, IQR: 9.9–12.9 on
pre-ATT, p = 0.0004), indicating that antibiotic treatment
successfully reduced the degree of anemia in the patient
population. As expected, the values of the inflammatory
markers were markedly decreased at 60 days of antimicro-
bial treatment (Fig. 2b). In addition, at the study enroll-
ment time point, the smear status did not associate with
significant changes expression profile of the biomarkers
Table 1 Characteristics of the study participants
Characteristic
N 73
Male – no. (%) 49 (84.48)
Median age – y (IQR) 41 (29–50.3)
Median hemoglobin – g/dL (IQR) 11.6 (9.9–12.9)
AFB+ sputum smear 52 (71.2)
Cavitary lung lesion – no. (%) 42 (57.5)
Smoking history – no. (%) 43 (74.13)
Alcoholism – no. (%) 53 (72.6)
Illicit drugs use – no. (%) 18 (31.03)
HIV/AIDS – no. (%) 8 (13.79)
Fever – no. (%) 39 (67.24)
Cough – no. (%) 45 (77.58)
Anemia – no. (%) 63 (86.3)
Hemoptysis – no. (%) 13 (22.41)
AFB acid-fast bacilli, IQR interquartile range
Anemia criteria was based on hemoglobin value below 13.5 g/dL for men or
12.0 g/dL for women
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(Fig. 2b). Upon treatment initiation, we observed that indi-
viduals who were AFB+ at pre-ATT remained with height-
ened levels of IL-6, IL-10 and IFN-γ compared to those
with negative smears (Fig. 2b, c). Of note, within each
group of patients (AFB− or AFB+), the circulating levels
of both IL-6 and IFN-γ did not significantly change upon
treatment initiation, whereas IL-10 levels were substan-
tially increased in both groups (Fig. 2c).
We next tested whether mycobacterial loads in spu-
tum smears could also reflect early treatment responses
in our patient population. We found that individuals
who remained with positive M. tuberculosis sputum cul-
tures at day 60 of treatment exhibited more frequently
higher AFB smear grades at pre-ATT than those who
experienced culture conversion (53.8 % of those with
culture positive at day 60 had AFB > 1+ at pre-ATT
vs. 18.8 % of those with culture negative at day 60,
p = 0.032; Fig. 2d). Logistic regression analysis adjusted
for age, gender and hemoglobin levels confirmed that an
AFB smear grade above 1+ was indeed associated with in-
creased risk for M. tuberculosis culture positivity at day
60 of ATT (Relative risk [RR] = 4.4; p = 0.037; Fig. 2d).
To prospectively depict the serum inflammatory pro-
files of PTB patients diverging in early ATT responses, we
performed an additional hierarchical cluster analysis of
the biomarker values at day 0 and 60 of treatment initi-
ation. This approach revealed that M. tuberculosis culture
positivity after treatment initiation was associated with
Fig. 1 Prospective immune profiling of pulmonary TB patients before and 60 days after anti-mycobacterial treatment initiation. a Levels of C-
reactive protein (CRP), indicated cytokines and erythrocyte sedimentation rate (ESR) were measured in serum samples from 73 patients with
pulmonary TB at day 0 and 60 of anti-tuberculous treatment (ATT). Data were analyzed using Wilcoxon matched pairs test. Dotted lines represent
median values detected in age- and gender-matched uninfected and healthy controls (n = 10), to serve as reference. b Network analysis was
performed based on Spearman correlation matrices as described in Methods. Each connecting line represents a statistically significant correlation
(p < 0.05). The strength (r value) and level of significance (p-value) for each significant correlation is shown in Additional file 1: Table S1. c A model
of principal component analysis (PCA) was employed to test whether combination of the markers could cluster the patients at different time
points of ATT (left panel). Vector analysis was further utilized to illustrate the influence of each marker in data distribution of the PCA model (center
panel). Delta variation of the indicated markers from day 0 to day 60 of ATT initiation (right panel). Data represent median and interquartile ranges.
d A second model of PCA in which all variable were included except from those with the largest delta variation from day 0 to day 60 of ATT was
designed. HC = healthy controls, PC = principal component
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sustained heightened circulating levels of IL-10 only,
whereas IL-6, IL-10 and IFN-γ remained at higher values
in the group of patients who had negative cultures at day
60 of ATT (Fig. 2e). Of note, within this study population,
3 patients ended up exhibiting drug resistance (all of those
were rifampicin resistant). Only 1 out of these 3 patients
remained sputum positive at day 60 of treatment. Our
conclusion in the context of this study is thus that the lack
of early sputum clearance detected in some patients evalu-
ated here was not directly related to drug resistance.
Nevertheless, this specific conclusion is weakened by the
very low numbers of drug resistant cases evaluated in the
present study.
Cavitary lung lesions and cytokine levels, AFB smear
status, sputum cultures and radiographic improvement of
lung disease in patients undergoing ATT
Cavitary lung disease increases TB and is described to
contribute to antibiotic failure and the emergence of
antibiotic resistance [22–24]. Given the fact that up to
57.5 % of our study population exhibited lung cavitations
on radiographic evaluation at the enrollment (Table 1),
we next examined the changes in the biomarker serum
concentrations upon ATT initiation in TB patients
stratified by cavitary disease. Of note, patients with cavi-
tary disease were similar to those with non-cavitary TB
with regard to age, gender, prevalence of symptoms, to-
bacco use, alcoholism history, HIV status and hemoglobin
levels levels (all with p > 0.05). Levels of CRP, IL-2 and IL-
4 consistently decreased n both groups of patients with
cavitary and non-cavitary disease (Fig. 3a). In addition, at
day 60 of ATT, CRP concentrations were found to be
higher in patients with pre-ATT cavitary lesions compared
to those with non-cavitary disease (Fig. 3a). Furthermore,
both IL-6 and IFN-γ levels remained unchanged upon
treatment initiation regardless of the cavitary disease sta-
tus (Fig. 3a). Values of ESR as well as concentrations of
TNF-α substantially decreased, whereas levels of IL-10 in-
creased, only in the subset of patients exhibiting cavitary
disease at pre-ATT (Fig. 3a). Aside from the CRP levels,
we observed no statistically significant differences in the
remaining biomarker values between patients with cavi-
tary lesions and those with non-cavitary disease at day 60
of ATT. Hierarchical cluster analyses of the median values
of each biomarker per study group revealed that TB pa-
tients summarized these findings (Fig. 3b). Notably, whilst
we detected increased frequency of pre-ATTAFB+ in spu-
tum smears from individuals with cavitary disease vs.
those with no lung cavitation (Fig. 3c), these clinical
groups were undistinguishable with regard to frequency of
M. tuberculosis culture positive and radiographic improve-
ment of lung lesions at day 60 of ATT (Fig. 3c).
Fig. 2 Inflammatory profile, mycobacterial loads and culture positivity at day 60 of antimicrobial treatment in PTB patients. a A hierarchical
clustering analysis (Ward’s method with bootstrap) was employed to show the immunological profile of TB patients with different AFB status in
smear samples at pre-ATT. Data was processed as described in Methods. In the heatmap, the squares represent values below or above the
median values (log10) of a given biomarker in the entire study population (n = 73). b The same hierarchical clustering analysis was performed to
compare the inflammatory profile of TB patients stratified according to the AFB status in sputum smears at pre-ATT and the study time points.
c Serum levels of the indicated cytokines were compared between day 0 and day 60 of ATT in TB patients presenting with positive or negative
AFB in sputum smears at study enrollment. Data were analyzed using the Wilcoxon matched pairs test. Significant p-values are shown. d Left
panel shows frequency of TB patients with AFB >1+ in sputum smears within the groups of individuals stratified by culture status at day 60 post
ATT initiation (positive culture at day 60, n = 13; negative culture, n = 53). Data were compared using the Fisher’s exact test. Right panel shows lo-
gistic regression analysis adjusted for age, gender and hemoglobin levels was performed to determine the association between AFB sputum
smear > +1 at pre-ATT and culture positivity at 60 day upon ATT initiation. e A hierarchical clustering analysis was employed to illustrate the in-
flammatory profile of TB patients stratified by treatment time point and culture status at day 60 after ATT initiation
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Radiographic improvement of lung disease in TB patients
upon ATT initiation is associated with pre-treatment
levels of C-reactive protein and AFB smears in sputum
Radiographic assessment of PTB patients during anti-
microbial treatment has been used as a tool to estimate
disease activity [25]. In the present study, the vast major-
ity of the patient population, (52 %) exhibited significant
radiographic improvement (38 out of 73 individuals)
assessed by a panel independent physician experts. Indi-
viduals displaying lower AFB smear grades (AFB < 2+) at
pre-ATT tended to present with radiographic improve-
ment of lung disease compared to those with higher
mycobacterial loads in sputum, however this difference
was not statistically significant (p = 0.118; Fig. 4a). Among
Fig. 3 Association between cavitary lung disease, systemic inflammation and radiological improvement of TB lung lesions. a Levels of C-reactive
protein (CRP), indicated cytokines and erythrocyte sedimentation rate (ESR) were compared between day 0 and 60 of anti-tuberculous treatment
(ATT) in TB patients with (n = 42) or without (n = 31) cavitary disease. The Wilcoxon matched pairs test was used to compare changes in the
biomarker levels between the timepoints in each clinical subgroup. The Mann–Whitney test was used to compare biomarker values between
cavitary vs. non-cavitary TB disease at different timepoint. Dotted lines represent median values detected in age- and gender-matched uninfected
and healthy controls (n = 10), to serve as reference. * p < 0.05; ** p < 0.01; *** p < 0.001. b A hierarchical clustering analysis (Ward’s method with
bootstrap) was employed to illustrate the inflammatory profile of TB patients stratified by treatment timepoint and cavitary lung disease at pre-
ATT. Asterisks highlight the parameters that exhibited statistically significant differences in one or more comparison [shown in (a)]. c frequency of
TB patients with or without cavitary TB exhibiting AFB+ smears at pre-ATT (left panel), positive M. tuberculosis sputum culture (center panel) and
improvement of lung lesions assessed by chest X-rays at day 60 of treatment.. Data were compared using the Fisher’s exact test
Fig. 4 Association between mycobacterial loads in sputum, systemic inflammation and radiological improvement of TB lung lesions. a Frequency
of individuals exhibiting radiological improvement of lung lesions assessed by chest x-ray in the groups of TB patients according to the indicated
AFB status in smear samples at pre-ATT. Data was analyzed using Fisher’s exact test. b Serum levels of CRP were compared between day 0 and
day 60 of ATT in TB patients stratified by improvement lung lesions assessed by chest X-ray. Data were analyzed using the Wilcoxon matched
pairs test. * p < 0.05; ** p < 0.01; *** p < 0.001. c Different models of regression analysis adjusted for age, gender and hemoglobin levels were
employed to determine the association between low AFB sputum smear grade (<2+), low serum levels of CRP (concentrations below the median
value of the entire study population, 4.7 mg/L) at pre-ATT and radiological improvement at day 60 of ATT
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all the inflammatory markers examined, only CRP values
exhibited statistically significant prospective changes in
patients stratified according to radiographic improvement
at day 60 of ATT. We observed that CRP levels decreased
in PTB patients undergoing ATT independently of the
status of the radiographic evaluation at day 60 (Fig. 4b).
Moreover, at day 60 of treatment, patients who had chest
X-ray improvement exhibited lower CRP serum concen-
trations than those who did not (Fig. 4b). We next per-
formed a logistic regression adjusted for age, gender and
hemoglobin levels to examine the association between
lower mycobacterial loads in sputum, lower concentra-
tions of CRP or both at pre-ATT and the odds for radio-
graphic improvement at day 60 of treatment. Importantly,
we detected a synergistic effect of low AFB counts and
low CRP values on odds for improvement in lung disease
(Fig. 4c). Individuals presenting with pre-ATT AFB smear
< 2+ and CRP levels < 4.7 mg/L were ten times more likely
to exhibit radiographic improvement of lung disease com-
pared to those with higher values of these parameters
(Relative risk: 10.0, 95 % CI: 2.4–40.0; p = 0.002; Fig. 4c).
Discussion
Several exploratory studies have evaluated the diagnostic
potential of cytokine biomarkers other than IFN-γ for
monitoring anti-tuberculous therapy [2, 3], but no pro-
spective study have measured simultaneously the direct
associations between mycobacterial loads, Th1/Th2 cyto-
kines, acute phase parameters and pulmonary lesions
upon treatment initiation, as we performed in our longi-
tudinal study. A recent systematic review by Clifford
et al. [26] identified only 12 longitudinal studies that
measured ex vivo serum cytokine concentrations with-
out a stimulation step during anti-TB treatment. The
largest studies were those by Azzuri et al. [27] and Wang
et al. [28], with 220 and 87 TB cases, respectively. Thus,
additional prospective studies assessing effects of ATT
on the host inflammatory profile are greatly needed, es-
pecially in endemic areas such as Brazil.
In the present study, we prospectively depict the
immune profile, microbial clearance and evolution of
radiographic lesions in 73 pulmonary TB patients
before and 60 days after anti-tuberculous treatment
initiation. Logistic regression analysis adjusted for age,
gender and hemoglobin levels confirmed that an AFB
smear grade above 1+ was indeed associated with
increased risk for M. tuberculosis culture positivity at
day 60 of ATT. These results confirm that monitoring
sputum and culture conversion may be a good indica-
tors of treatment outcome for drug-sensitive TB but
may present low sensitivity and modest specificity for
predicting failure and relapse [29]. In our study, we
found that pre-ATT mycobacterial loads in sputum
and systemic inflammation synergistically associated
with the status of radiographic lesions during treat-
ment. This approach could potentially improve the
predictive value of non-favorable outcomes associated
with ATT in future clinical trials.
Within the inflammatory parameters evaluated, values
of CRP, IL-2, IL-4, TNF-α and ESR significantly de-
creased upon treatment initiation similarly to other
studies [28, 30–36]. On the converse, IL-10 levels sub-
stantially increased at day 60 of ATT, as also described
elsewhere [5, 27, 28, 30, 33–40]. Nevertheless, the re-
ports on the changes in IL-10 levels are conflicting, as
other studies have described decreases of the systemic
levels of this cytokine during ATT [5, 27, 28, 35]. It is
possible that differences in study populations as well as
distinct epidemiological/genetic background could ex-
plain these conflicting findings.
In our study, concentrations of IL-6 and IFN-γ
remained unchanged during the anti-TB treatment in
disagreement with different investigations where IL-6
and IFN-γ tended to decrease during ATT [28, 30, 31,
33, 36–38] and with other reports which showed in-
creases in IFN-γ levels [39, 41–43]. Additional studies
systematically investigating patients from different ethni-
city/genetic backgrounds should be performed to narrow
down the mechanisms underlying these discrepancies.
Importantly, at day 60 of treatment, the cytokine net-
work of associations based on Spearman ranks revealed
that the cytokine exhibiting the higher number of signifi-
cant correlations with the remaining biomarkers was
shifted from TNF-α to IFN-γ. It is possible that these
two cytokines may be critical for driving activation of
specific immune pathways evoked by ATT; however, this
hypothesis requires additional mechanistic studies to be
tested.
Multidimensional analyses revealed that ESR, IL-2,
IL-4 and CRP were the parameters with the highest
power to discriminate individuals before and after treat-
ment initiation. As highlighted previously [44], our find-
ings indicate that monitoring acute phase parameters
(ESR, CRP), Th1 cytokines (IL-2) and anti-inflammatory
(IL-4) may help understanding the multidimensionality
of immunopathology in TB and point to novel potential
therapeutic targets for pulmonary TB. Recently, Mihret
et al. [39], while evaluating HIV negative and positive
TB cases, have demonstrated that the ratios of IFN-γ/
IL-10 and IFN-γ/IL-4 display significant increases after
treatment in HIV negative TB cases but not in HIV
positive TB cases.
Remarkably, we observed that individuals who were
AFB+ at pre-ATT remained with heightened levels of
IL-6, IL-10 and IFN-γ upon treatment initiation com-
pared to those with negative smears, similarly to that de-
scribed by Djoba et al. [33] and Chowdhury et al. [37]
where serum levels of IFN-γ, TNF-α, IL-6 and IL-10
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were shown to be directly associated with the bacterial
load. As expected, the values of the pro-inflammatory
markers were markedly decreased at 60 days of anti-
microbial treatment. Our results also revealed that there
is a strong association between pre-treatment mycobac-
terial loads and risk for culture positivity at day 60 of
ATT initiation similarly to results described by Djoba et
al. [33].
The apparent association between increased levels of
only IL-10, among all the other markers, and presence
of M. tuberculosis culture positivity at day 60 of ATT is
intriguing and may underline a potential inability of the
immune system to clear the bacteria from the lung. In-
deed, IL-10 induction is described to be a potential scape
mechanism used by M. tuberculosis to survive in macro-
phages [45]. M. tuberculosis can be recognized by TLR-2
and induce production of IL-10, that promotes differenti-
ation into a M2-like macrophage phenotype and possibly
Th2 adaptive responses [46]. Moreover, recent studies
demonstrated a direct association between TLR2 poly-
morphisms and enhanced bacterial loads in pulmonary
tuberculosis patients [45]. Our group is currently assessing
the influence of immune related polymorphisms in cyto-
kine levels in TB patients undergoing ATT.
More recently, some studies have reported the associ-
ation between sputum conversion at 60 day of TB treat-
ment with decreases in serum levels of CRP, CXCL10,
IL-17, MMP-8, as well as with cytokine responses after
M. tuberculosis-specific in vitro stimulation of peripheral
blood. Moreover, sputum conversion has also been asso-
ciated with decreases in IFN-γ, TNF-α and IL-2 levels as
well as in frequency of IFN-γ+CD4+ T-cells that express
immune activation markers CD38 and HLA-DR and the
proliferation marker Ki-67 in peripheral blood [32, 34,
46–49]. Whether our findings reflect changes in T-cell
compartment or in other immune cells deserves further
investigation.
In the present study, we detected an increased fre-
quency of AFB+ smears at pre-ATT in patients present-
ing with cavitary lesions. This finding is consistent with
the idea that cavitary lesions increase risk for TB trans-
mission [22, 24]. Interestingly, bilateral cavity formation
is thought to be the most significant predictor of treat-
ment failure for extensively drug-resistant TB [23]. Our
current understanding of the mechanisms implicated in
cavity formation is still elusive and derive mostly from
experimental models and observational studies of hu-
man specimens [50, 51]. We observed that the circulat-
ing levels of all the parameters assessed could not
distinguish patients with non-cavitary disease from those
presenting with cavitary lung lesions at pre-treatment. In
addition, the magnitude of changes in levels of IL-2, IL-4,
IL-6 and IFN-γ between day 0 and 60 of ATT was similar
between the groups of patients stratified according to
cavitary disease status. Although CRP concentrations con-
sistently decreased at day 60 of ATT in both subgroups of
patients, individuals with cavitary disease exhibited height-
ened values compared to patients with non-cavitary TB.
Furthermore, serum levels of IL-10 significantly increased
while TNF-and ESR values substantially decreased from
day 0 to day 60 of ATT in patients with cavitary TB but
not in those with non-cavitary lung disease. These differ-
ential changes detected may indicate that individuals with
lung cavities exhibit a slightly different inflammatory re-
sponse to ATT. However, these disparities in biomarker
levels may not be biologically relevant as they did not re-
flect differences in early treatment responses, as the fre-
quencies of patients presenting with culture positive or
improvement of lung lesions by radiographic evaluation
on day 60 of ATT were similar between the subgroups
with or without cavitary TB. It is possible that de directly
observed therapy employed here, together with the close
monitoring of patients who remained in the hospital for
the first 60 days of treatment, resulted in good treatment
response regardless of cavitary disease.
Individuals presenting with pre-ATT AFB smear < 2+
and CRP levels < 4.7 mg/L were more than 12 times
more likely to exhibit radiographic improvement of lung
disease. Few studies have evaluated the interaction
within bacterial load, inflammation response and radio-
graphic changes [33]. Nevertheless, other studies have
reported associations between a number of cytokines,
such as TNF-α, IL-1β, IL-6, IL17 and TGF-β1, and
radiographic TB lung disease presentation [30, 33, 36,
48, 52]. CRP is acute inflammatory protein whose pro-
duction by hepatic cells is stimulated by TNF-α, IL-1
and IL-6. This protein has important functions, which
include induction of inflammatory responses and partici-
pation in immune activation following infection. Many
authors suggest that a fine control of inflammatory re-
sponses is crucial to promote clinical and microbiological
improvement of TB patients [8, 10, 53]. Exhaustive in-
flammatory responses lead to immunopathology-driven
pulmonary injury, which directly impacts disease severity
in pulmonary tuberculosis [12, 54]. Lower CRP concentra-
tions found in a subset of TB patients prior to ATT may
be indicative of a mild/moderate systemic inflammatory
response reflected by increase odds for improvement in
chest-X-ray 60 days after treatment initiation.
The strengths of our study include: a) cohort of
hospital-based pulmonary TB patients that assessed sim-
ultaneously the direct associations between mycobacter-
ial loads, Th1/Th2 cytokines, acute phase parameters
and pulmonary lesions upon treatment initiation, b) our
study population was followed up very closely to assure
treatment adherence: during the study period, all pul-
monary TB patients remained hospitalized and received
anti-TB drugs under directly observed manner, c) the
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personnel performing the laboratory and chest radio-
graphs analysis were unaware of the treatment out-
comes, d) innovative statistical analyses employing
multidimensional approaches were used to define a bio-
signature that better relates to the clinical outcomes
assessed.
Our study has some limitations. We did not evaluate
other diseases, which could result in similar disease
presentation than TB. Identification of a biosignature
distinguishing TB from other clinical disease groups has
been published by us and others [9, 10, 55–57] and it
was not an aim of the present study. Our study has a very
narrowed goal of testing associations between bacillary
loads, systemic inflammation and radiological changes in
individuals with active TB undergoing treatment. More-
over, we have not screened our patients for a number of
co-infections, such as viral hepatitis and helminth in-
fections, as well as for comorbidities such as steato-
hepatitis, which could affect immune responses in TB
patients [58, 59]. Additional studies with larger numbers
of patients will be required to investigate whether the re-
sults described here in terms of prospective changes in in-
flammatory biomarkers in the context of ATT are
considerably affected by these co-morbidities. We have
assessed serum levels of inflammatory markers and have
not studied specific cellular immune responses against M.
tuberculosis infection. The use of serum samples may re-
sult in lower specificity than measuring cytokine responses
induced by stimulations with TB antigen in cell cultures.
Few HIV positive TB cases were included in the analysis,
due to the lower prevalence of TB-HIV co-infection in our
study setting. Finally, we did not evaluate different pat-
terns of the host immune response according to different
M. tuberculosis lineages [60]. Nevertheless, our results
were able to demonstrate unique associations between
host inflammatory markers in serum and microbiological
and radiological outcomes after the onset of anti-TB treat-
ment. Due to the relatively small number of patients stud-
ied in our exploratory study, it would be important to
validate the results reported here in additional cohorts
with larger patient populations as well as in different epi-
demiological settings.
Conclusions
In the present study, we identified host biomarkers that
could potentially be used in addition to the clinical
evaluation of TB patients to estimate sputum clearance
and evolution of radiographic lung lesions upon initi-
ation of anti-TB treatment. The relationship between
CRP with bacterial loads in sputum and chest-X-ray de-
serves future mechanistic investigation. Additionally, our
findings indicating a direct relationship between higher
bacterial loads sputum at pre-ATT and no improvement
of chest-X-ray at day 60 of treatment argue that there
was a lack of mycobacterial control in a subset of pa-
tients. Our results revealed that lower concentrations of
CRP are related with improvement of chest-X-ray, sug-
gesting the fine control of inflammatory response in
these patients. Understanding the inflammatory mecha-
nisms associated with treatment outcomes in pulmonary
TB may lead to new therapeutic proposals to diminish
the tuberculosis disease burden.
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